Loading...
Ara-290
Add to Wishlist
Non-Hematopoietic EPO Peptide for Tissue Protection
In Stock
10mg
$60.00$72.00
You Save
$12.00In Stock — Ships Same Day
Includes
10mg research compound
Third-party lab tested
Free shipping on orders over $150
30-day money-back guarantee
Overview
ARA-290 (also known as cibinetide) is an 11-amino acid synthetic peptide (sequence: HBSP, helix B surface peptide) derived from the three-dimensional structure of erythropoietin's helix B surface region. It selectively activates the innate repair receptor (IRR), a heterodimer composed of the erythropoietin receptor (EPOR) and the beta common receptor (betaCR2/CD131), which is expressed on monocytes, macrophages, Schwann cells, and endothelial cells in damaged or inflamed tissues. Critically, ARA-290 does not bind the classical homodimeric EPOR responsible for erythropoiesis, meaning it provides tissue-protective and anti-inflammatory effects without stimulating red blood cell production or the thrombotic risks associated with erythropoietin administration. Published clinical research in sarcoidosis patients demonstrated improvements in small fiber neuropathy symptoms and corneal nerve fiber density, while preclinical models have shown neuroprotective effects in diabetic neuropathy and reduced inflammatory cytokine production. ARA-290 represents a mechanistically unique approach to tissue repair — leveraging the cytoprotective signaling of the EPO pathway without its hematopoietic effects. Ongoing research is exploring applications in chronic neuropathic conditions, metabolic tissue damage, and inflammatory disorders where the innate repair receptor pathway is upregulated.
Handling & Storage
Published research protocols reference daily subcutaneous administration. Store refrigerated at 2-8°C.
Published Research Protocols
Published research protocols reference 1-4mg daily subcutaneously in 28-day cycles. Consult applicable literature for specific research applications.
Research Applications
Innate Repair Activation
Selectively activates the innate repair receptor (EPOR/betaCR2 heterodimer) expressed on tissue-resident macrophages, Schwann cells, and endothelial cells at sites of injury or inflammation. This receptor is distinct from the classical erythropoietin receptor, allowing ARA-290 to trigger cytoprotective PI3K/Akt signaling without stimulating red blood cell production.
Initial effects within first month
Research Studies
Anti-Inflammatory
Reduces production of pro-inflammatory cytokines including TNF-alpha, IL-6, and IL-1beta through modulation of macrophage polarization from M1 (pro-inflammatory) to M2 (anti-inflammatory/reparative) phenotype. Preclinical research demonstrated significant reductions in systemic inflammatory markers and tissue damage in multiple organ injury models.
Initial effects within first month
Research Studies
Neuropathy Research
Clinical studies in sarcoidosis patients demonstrated improvements in small fiber neuropathy symptoms and increased corneal nerve fiber density after ARA-290 administration. Preclinical diabetic neuropathy models showed enhanced Schwann cell survival and nerve fiber regeneration, suggesting a direct neurotrophic effect mediated through innate repair receptor signaling.
Initial effects within first month
Research Studies
Frequently Asked Questions
How does ARA-290 differ from erythropoietin (EPO)?
ARA-290 selectively activates the innate repair receptor (EPOR/betaCR2 heterodimer) without binding the classical homodimeric EPOR that stimulates red blood cell production. This means ARA-290 provides tissue-protective and anti-inflammatory signaling without erythropoiesis, eliminating the thrombotic and polycythemia risks associated with EPO administration.
What clinical research has been conducted on ARA-290?
ARA-290 (cibinetide) has been investigated in Phase 2 clinical studies in patients with sarcoidosis-related small fiber neuropathy. Published results demonstrated improvements in neuropathic symptoms and corneal nerve fiber density. Additional preclinical research has explored its effects in diabetic neuropathy, cardiac ischemia-reperfusion injury, and chronic inflammatory conditions.
How should ARA-290 be reconstituted and stored?
Reconstitute lyophilized ARA-290 with bacteriostatic water by slowly injecting along the vial wall. As a short 11-amino acid peptide, ARA-290 dissolves rapidly. Store unreconstituted peptide at -20°C; after reconstitution, refrigerate at 2-8°C and use within 30 days. Minimize freeze-thaw cycles.
What purity verification does PEPCELL perform on ARA-290?
Each ARA-290 batch is independently tested at Janoshik Analytical Laboratory using HPLC for purity determination and mass spectrometry for sequence identity confirmation. Current batches test at 99.7% purity, with batch-specific Certificates of Analysis available on the product page.
Is ARA-290 intended for human use?
ARA-290 is sold exclusively for in-vitro research, laboratory investigation, and educational purposes. While cibinetide has been studied in clinical trials, this research-grade product is not an FDA-approved drug and is not intended for human consumption or self-administration.
Important Notice
Not for human consumption. This product is sold exclusively for in-vitro research and laboratory use. It is not a drug, supplement, food item, or cosmetic and has not been evaluated by the FDA.
The research data and clinical references cited on this page are provided for educational reference only and do not constitute medical advice. This product must be handled by qualified research professionals in accordance with all applicable institutional and regulatory guidelines.
Use is restricted to qualified researchers or laboratories operating within appropriate legal and ethical research guidelines. By purchasing, you confirm you are acquiring this product solely for lawful research purposes.
Research Articles
Published research and educational content related to Ara-290
Guides11 min read
The Complete Guide to Peptide Reconstitution for Research
A step-by-step guide to reconstituting lyophilized research peptides, covering solvent selection, concentration calculations, proper technique, post-reconstitution storage, and common mistakes to avoid.
Michael TorresContent Director
Research11 min read
BPC-157 vs TB-500: Comparing Recovery Research Peptides
A detailed comparison of two of the most studied recovery peptides in preclinical research, examining their distinct mechanisms, published findings, and how investigators approach studying them individually and in combination.
Dr. Sarah ChenChief Science Officer
Research12 min read
Growth Hormone Secretagogues: CJC-1295, Ipamorelin, GHRP-2 & GHRP-6 Research Overview
A comprehensive research overview of the major growth hormone secretagogues, including GHRH analogs and ghrelin receptor agonists, their mechanisms of action, selectivity profiles, and published preclinical and clinical findings.
Dr. James ParkResearch Analyst
Research14 min read
Immune-Modulating Peptides: Thymosin Alpha-1, LL-37, and KPV Research
An overview of three key peptides being studied for their immune-modulating properties, covering innate and adaptive immune mechanisms, published research findings, and the current state of immunopeptide science.
Michael TorresContent Director